日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

galunisertib(一种 TGFβRI 小分子抑制剂)靶向 TGFβ 通路,可促进抗肿瘤免疫,从而产生持久、完全的缓解,可作为单一疗法或与检查点阻断联合使用

Rikke B Holmgaard, David A Schaer, Yanxia Li, Stephen P Castaneda, Mary Y Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R Manro, Philip W Iversen, David Surguladze, Gerald E Hall, Ruslan D Novosiadly, Karim A Benhadji, Gregory D Plowman, Michael Kalos, Kyla E Driscoll

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

MET 靶向抗体 (emibetuzumab) 和激酶抑制剂 (merestinib) 作为单一药物或联合用于治疗 MET 外显子 14 跳跃的癌症模型

S Betty Yan, Suzane L Um, Victoria L Peek, Jennifer R Stephens, Wei Zeng, Bruce W Konicek, Ling Liu, Jason R Manro, Volker Wacheck, Richard A Walgren

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

首创转化生长因子-β 受体 I 型抑制剂 galunisertib(LY2157299 一水合物)的临床前评估

Jonathan M Yingling, William T McMillen, Lei Yan, Huocong Huang, J Scott Sawyer, Jeremy Graff, David K Clawson, Karen S Britt, Bryan D Anderson, Douglas W Beight, Durisala Desaiah, Michael M Lahn, Karim A Benhadji, Maria J Lallena, Rikke B Holmgaard, Xiaohong Xu, Faming Zhang, Jason R Manro, Philip

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

激活Wnt/β-Catenin通路治疗黑色素瘤——新型糖原合酶激酶3选择性抑制剂LY2090314的应用

Jennifer M Atkinson, Kenneth B Rank, Yi Zeng, Andrew Capen, Vipin Yadav, Jason R Manro, Thomas A Engler, Marcio Chedid

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

LY2875358 是一种中和和内化抗 MET 二价抗体,可抑制 HGF 依赖性和 HGF 非依赖性的 MET 活化和肿瘤生长

Ling Liu, Wei Zeng, Mark A Wortinger, S Betty Yan, Paul Cornwell, Victoria L Peek, Jennifer R Stephens, Jonathan W Tetreault, Jinqi Xia, Jason R Manro, Kelly M Credille, Darryl W Ballard, Patricia Brown-Augsburger, Volker Wacheck, Chi-Kin Chow, Lihua Huang, Yong Wang, Irene Denning, Julian Davies, Y

Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET

LY2801653(包括 MET 在内的多种癌激酶的抑制剂)可抑制非小细胞肺癌的肿瘤生长和转移

Wenjuan Wu, Chen Bi, Kelly M Credille, Jason R Manro, Victoria L Peek, Gregory P Donoho, Lei Yan, John A Wijsman, S Betty Yan, Richard A Walgren

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

LY2801653 是一种口服生物可利用的多激酶抑制剂,对 MET、MST1R 和其他癌蛋白具有强效活性,并在小鼠异种移植模型中表现出抗肿瘤活性

S Betty Yan, Victoria L Peek, Rose Ajamie, Sean G Buchanan, Jeremy R Graff, Steven A Heidler, Yu-Hua Hui, Karen L Huss, Bruce W Konicek, Jason R Manro, Chuan Shih, Julie A Stewart, Trent R Stewart, Stephanie L Stout, Mark T Uhlik, Suzane L Um, Yong Wang, Wenjuan Wu, Lei Yan, Wei J Yang, Boyu Zhong, 

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

患者来源的急性髓系白血病 (AML) 骨髓细胞表现出不同的细胞内激酶磷酸化模式

Keith Shults, Leanne Flye, Lisa Green, Thomas Daly, Jason R Manro, Michael Lahn